Pharma Deals Review, Vol 2008, No 98 (2008)

Font Size:  Small  Medium  Large

BioMarin Licenses Summit’s Muscular Dystrophy Programme

Taskin Ahmed

Abstract


BioMarin Pharmaceutical and Summit Corporation plc entered into an exclusive worldwide licensing agreement for Summit’s preclinical candidate, SMT C1100, and all follow-on molecules for the treatment of Duchenne muscular dystrophy.

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.